Press Releases All News 2020 2019 2018 2017 2016 2015 2014 Relmada Therapeutics Announces Uplisting to the Nasdaq Global Select Market® July 13, 2020 Relmada Therapeutics Announces Notice of Allowance for Patent in Canada Covering REL-1017 for Treatment of Psychiatric Symptoms June 23, 2020 Relmada Therapeutics to Present at the Goldman Sachs 41st Annual Global Healthcare Conference June 9, 2020 Relmada Therapeutics to Present at the Jefferies 2020 Virtual Healthcare Conference May 29, 2020 Relmada Therapeutics Announces Outcome of End-of-Phase 2 Meeting with FDA for REL-1017 for Adjunctive Treatment of Patients with Major Depressive Disorder May 27, 2020 Relmada Therapeutics Appoints Molly Harper as Executive Vice President of Operations May 26, 2020 Relmada Therapeutics Enhances Senior Leadership Team with Appointment of Brian A. Walter, Ph.D., as Vice President of Regulatory Affairs April 28, 2020 Relmada Therapeutics Solidifies its R&D Leadership Team with the Appointment of Marc de Somer, MD, MBA, ScD, MPH, MSc, as Senior Vice President, Clinical Development and Safety March 31, 2020 Relmada Therapeutics Strengthens Scientific Leadership Team with the Appointment of Judy Caron, Ph.D., as Vice President of Drug Development March 24, 2020 Relmada Therapeutics Appoints CNS Specialist Thomas C. Wessel, M.D., Ph.D., as Executive Vice President, Head of Research and Development March 9, 2020 1 2 3 4 5 6 7 8 9 10 ...14 Next »
Relmada Therapeutics Announces Notice of Allowance for Patent in Canada Covering REL-1017 for Treatment of Psychiatric Symptoms June 23, 2020
Relmada Therapeutics to Present at the Goldman Sachs 41st Annual Global Healthcare Conference June 9, 2020
Relmada Therapeutics Announces Outcome of End-of-Phase 2 Meeting with FDA for REL-1017 for Adjunctive Treatment of Patients with Major Depressive Disorder May 27, 2020
Relmada Therapeutics Enhances Senior Leadership Team with Appointment of Brian A. Walter, Ph.D., as Vice President of Regulatory Affairs April 28, 2020
Relmada Therapeutics Solidifies its R&D Leadership Team with the Appointment of Marc de Somer, MD, MBA, ScD, MPH, MSc, as Senior Vice President, Clinical Development and Safety March 31, 2020
Relmada Therapeutics Strengthens Scientific Leadership Team with the Appointment of Judy Caron, Ph.D., as Vice President of Drug Development March 24, 2020
Relmada Therapeutics Appoints CNS Specialist Thomas C. Wessel, M.D., Ph.D., as Executive Vice President, Head of Research and Development March 9, 2020
